English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Treatment options for β-lactamase-producing Enterobacterales are limited, particularly for infections caused by metallo-β-lactamase (MBL)-producing strains. The β-lactam/non-β-lactam β-lactamase inhibitor combination aztreonam-avibactam (ATM-AVI) is active  in vitro  against Enterobacterales isolates carrying MBLs, including those co-producing β-lactamases of Class A, C, and some class D enzymes. This study evaluated the  in vitro  activity of ATM-AVI and comparators against Enterobacterales isolates collected in 2015-2019 from patients with bloodstream infections (BSI) as part of the ATLAS program.    Methods  Non-duplicate clinical isolates were collected in 53 countries in Europe, Latin America, Asia/Pacific (excluding mainland China and India), and Middle East/Africa. Susceptibility testing was performed by CLSI broth microdilution and interpreted using CLSI 2021 and FDA (tigecycline) breakpoints. ATM-AVI was tested at a fixed concentration of 4 µg/mL AVI. MDR was defined as resistant (R) to ≥3 of 7 sentinel drugs: amikacin, aztreonam, cefepime, colistin, levofloxacin, meropenem, and piperacillin-tazobactam. PCR and sequencing were used to determine the β-lactamase genes present in all isolates with meropenem MIC >1 µg/mL, and  Escherichia coli ,  Klebsiella  spp. and  Proteus mirabilis  phenotypically positive for ESBL activity (2015) or with aztreonam or ceftazidime MIC >1 µg/mL (2016-2019).    Results  ATM-AVI was active  in vitro  against Enterobacterales isolates from BSI (MIC 90 , 0.12 µg/mL), with 99.97% of isolates inhibited by ≤8 µg/mL of ATM-AVI, including 100% of isolates that produced MBLs. ATM-AVI tested with MIC 90  values of 0.5 µg/mL against subsets of cefepime-nonsusceptible (NS), meropenem-NS, amikacin-NS, colistin-resistant, and MBL-positive Enterobacterales (Table). The tested β-lactam comparators showed susceptibility of < 79% against these subsets of resistant isolates.  Results TableConclusion  Based on MIC 90  values, ATM-AVI was the most potent agent tested against drug-resistant and MBL-positive subsets of Enterobacterales collected from BSI. The promising  in vitro  activity of ATM-AVI warrants further development of this combination for treatment of BSI caused by drug-resistant Enterobacterales.    Disclosures    Sibylle Lob, PhD ,  IHMA  (Employee) Pfizer, Inc.  (Independent Contractor)  Krystyna Kazmierczak, PhD ,  IHMA  (Employee) Pfizer, Inc.  (Independent Contractor)  Francis Arhin, PhD ,  Pfizer, Inc.  (Employee)  Daniel F. Sahm, PhD ,  IHMA  (Employee) Pfizer, Inc.  (Independent Contractor)

open forum infectious diseases

1252. <i>In Vitro</i> Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales from Patients with Bloodstream Infections collected during the ATLAS Global Surveillance Program, 2015-2019

1252. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales from Patients with Bloodstream Infections collected during the ATLAS Global Surveillance Program, 2015-2019